

CSD/BSE&NSE/RPT/2022-23 May 20, 2022

To **The General Manager Department of Corporate Services BSE Limited** 25th Floor, P. J. Towers,

Dalal Street, Mumbai - 400 001

**Scrip Code: 530239 Scrip Symbol: SUVEN** 

Dear Sir/Madam,

Sub: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

To

The Manager

**Listing Department** 

**National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex** 

Bandra (E), Mumbai - 400 051

Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions and balances for the half year ended March 31st, 2022.

This is for your information and record.

Thanking you,

Yours faithfully,

For Suven Life Sciences Limited

Shrenik Soni

**Company Secretary** 

Encl.: as above

Personnel

Mrs J.A.S. Padmaja

Key Managerial

Sitting fee

Limited

Suven Life Sciences

Disclosure of related party transactions for the six months from October'21 to March'22										Rs.In Lakhs								
SI		ering	Details of the	e cour	iterparty	Type of related party transaction (see Note 5)	Value of the related party transaction as approved by the audit committee (see Note 6a)	Value of transaction during the reporting			Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such stransaction was undertaken.  In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments corporate deposits, advances or investments							
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost (see Note 7)	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
	Suven Life Sciences Limited		Suven Neuro Sciences Inc., USA		Wholly Owned Subsidary	Investment made	Not Applicable	3,402.19	34666.97	38069.16								
	2 Suven Life Sciences Limited		Suven Pharmaceuticals Limited		Company under the Control of Key Managerial Personnel	Leace Rental	109.79 p.a.	55.41										
	3 Suven Life Sciences Limited		Suven Pharmaceuticals Limited		Company under the Control of Key Managerial Personnel	Rendering of Services	2500.00 Per	365.09										
	Suven Life Sciences Limited		Suven Pharmaceuticals Limited		Company under the Control of Key Managerial Personnel	Purchase of material	Financial Year	126.22										
	5 Suven Life Sciences Limited		Mrs Sudha Rani Jasti		Key Managerial Personnel	Short term employee benefits	Not Applicable	113.94										
	6 Suven Life Sciences Limited		Prof. Dr. Seyed E. Hasnain	1	Key Managerial Personnel	Sitting fee	Not Applicable	1.30										
7	7 Suven Life Sciences Limited		Mr M Gopalakrishna		Key Managerial Personnel	Sitting fee	Not Applicable	1.80										
	8 Suven Life Sciences Limited		Mr Santanu Mukherjee		Key Managerial Personnel	Sitting fee	Not Applicable	1.70										

1.50

Not Applicable